Literature DB >> 17491672

Immunotherapy after recent-onset type 1 diabetes: combinatorial treatment for achieving long-term remission in humans?

Damien Bresson, Matthias von Herrath.   

Abstract

Entities:  

Year:  2004        PMID： 17491672      PMCID： PMC1783548          DOI： 10.1900/RDS.2004.1.108

Source DB:  PubMed          Journal:  Rev Diabet Stud        ISSN： 1613-6071


× No keyword cloud information.
  20 in total

1.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

Authors:  Kevan C Herold; William Hagopian; Julie A Auger; Ena Poumian-Ruiz; Lesley Taylor; David Donaldson; Stephen E Gitelman; David M Harlan; Danlin Xu; Robert A Zivin; Jeffrey A Bluestone
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

2.  Intradermal or oral delivery of GAD-encoding genetic vaccines suppresses type 1 diabetes.

Authors:  Alice F Li; Alan Escher
Journal:  DNA Cell Biol       Date:  2003-04       Impact factor: 3.311

3.  Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference.

Authors:  D Homann; T Dyrberg; J Petersen; M B Oldstone; M G von Herrath
Journal:  J Immunol       Date:  1999-08-15       Impact factor: 5.422

Review 4.  Are there unique autoantigens triggering autoimmune diseases?

Authors:  J F Bach; S Koutouzov; P M van Endert
Journal:  Immunol Rev       Date:  1998-08       Impact factor: 12.988

5.  TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.

Authors:  Mériam Belghith; Jeffrey A Bluestone; Samia Barriot; Jérôme Mégret; Jean-François Bach; Lucienne Chatenoud
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

6.  Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide.

Authors:  Nathan R Martinez; Petra Augstein; Antonis K Moustakas; George K Papadopoulos; Silvia Gregori; Luciano Adorini; David C Jackson; Leonard C Harrison
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

7.  Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23).

Authors:  D Daniel; D R Wegmann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

8.  Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide.

Authors:  David G Alleva; Amitabh Gaur; Liping Jin; Dale Wegmann; Peter A Gottlieb; Anil Pahuja; Eric B Johnson; Theresa Motheral; Amy Putnam; Paul D Crowe; Nicholas Ling; Stefen A Boehme; Paul J Conlon
Journal:  Diabetes       Date:  2002-07       Impact factor: 9.461

9.  T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors.

Authors:  Alexandra Zanin-Zhorov; Gabriel Nussbaum; Susanne Franitza; Irun R Cohen; Ofer Lider
Journal:  FASEB J       Date:  2003-06-17       Impact factor: 5.191

Review 10.  Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?

Authors:  Kevan C Herold; Lesley Taylor
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.